Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Adriana Figueroa Diaz

Dermatology San German, PR Medical Doctor

NPI 1386143329 CMS profile 11324453

Torre San Vicente De Paul Suite 403, Carr No 2 Km 173.4 Bo Cain Alto, San German, PR 00683

Open in the dashboard

General payments

$3,842

133 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Adriana Figueroa Diaz of San German, PR is reported in the CMS Open Payments database as having received $3,842 across 133 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 59th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $393 13
2024 General $1,154 42
2023 General $1,312 50
2022 General $983 28

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Adriana Figueroa Diaz
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Adriana Figueroa Diaz were reported at $393. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Adriana Figueroa Diaz Dermatology median Middle half National median
2019 $0 $454 $129–$1,240 $163
2020 $0 $235 $81–$756 $114
2021 $0 $377 $108–$1,108 $132
2022 $983 $514 $143–$1,391 $149
2023 $1,312 $607 $159–$1,674 $160
2024 $1,154 $751 $204–$1,903 $164
2025 $393 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. AbbVie, Inc. $1,512 63 payments
  2. Genzyme Corporation $344 13 payments
  3. E.R. Squibb & Sons, L.L.C. $316 10 payments
  4. Janssen Biotech, Inc. $315 3 payments
  5. Janssen Pharmaceuticals, Inc $293 12 payments
  6. Eli Lilly Export S.A. Puerto Rico Branch $228 10 payments
  7. PBG Puerto Rico LLC $217 9 payments
  8. Sanofi-Aventis U.S. LLC $190 2 payments
  9. LEO Pharma Inc. $145 2 payments
  10. Lilly USA, LLC $120 1 payment
  11. Other $163 8 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $3,447 128 payments
  2. Education $395 5 payments
Products named General payments · program years 2022–2025
  1. RINVOQ $729 30 payments
  2. DUPIXENT $700 21 payments
  3. TREMFYA $608 15 payments
  4. SKYRIZI $563 23 payments
  5. SOTYKTU $316 10 payments
  6. CIBINQO $210 9 payments
  7. TALTZ $178 8 payments
  8. LITFULO $147 6 payments
  9. ADBRY $145 2 payments
  10. HUMIRA $134 6 payments
  11. Other $348 16 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

277

Median for Dermatology: 534

Drug cost

$10,410

Median for Dermatology: $67,151

Branded share of claims

5.4%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clobetasol Propionate Generic 31 $2,144
Calcipotriene Generic 14 $1,881
Ketoconazole Generic 62 $1,487
Betamethasone Valerate Generic 30 $1,058
Metronidazole Generic 16 $906
Betamethasone Diprop Augmented Betamethasone/Propylene Glyc Brand 15 $787
Desonide Generic 19 $714
Triamcinolone Acetonide Generic 35 $609
Mometasone Furoate Generic 17 $529
Hydrocortisone Generic 19 $152

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $250
$250 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $241
$241 — —
SKYRIZI
  • AbbVie, Inc. $154
$154 — —
TALTZ
  • Eli Lilly Export S.A. Puerto Rico Branch $101
$101 — —
TREMFYA
  • Janssen Pharmaceuticals, Inc $75
$75 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

133 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Puerto Rico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record